drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An investigational CD3 T‑cell engager bispecific antibody (protein immunotherapy) that binds CD3 on T cells and a B‑cell tumor antigen to redirect and activate cytotoxic T cells against malignant B cells in relapsed/refractory B‑cell NHL; administered subcutaneously or intravenously with dose escalation to define RP2R.
nci_thesaurus_concept_id
C188792
nci_thesaurus_definition
A fully human effector-silent Fc immunoglobulin G1 (IgG1) trispecific antibody targeting the tumor-associated antigens (TAAs) B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29) and cluster of differentiation 20 (CD20), and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD79b/CD20/CD3 trispecific antibody JNJ-80948543 targets and binds to CD79b- and/or CD20-expressing tumor B-cells and CD3 antigen on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to CD79b- and/or CD20-expressing tumor B-cells, resulting in CTL-mediated killing of tumor cells. CD79b, a critical receptor for successful B-cell development and part of the B-cell receptor (BCR) signaling complex, is widely expressed in certain subtypes of B-cell lymphomas. CD20 is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.
drug_mesh_term
Antibodies, Bispecific
drug_category
TRISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous, Intravenous
drug_mechanism_of_action
Fully human effector-silent Fc IgG1 trispecific antibody that binds CD79b and CD20 on B-cell tumors and CD3 on T cells, redirecting and activating cytotoxic T cells to kill malignant B cells via immune-synapse formation and granzyme/perforin-mediated lysis.
drug_name
JNJ-80948543
nct_id_drug_ref
NCT06660563